Dallas, Texas (PRWEB) April 15, 2015
The report “Scar - Pipeline Review, H1 2015” provides comparative analysis on the therapeutic development for Scar. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available at http://www.rnrmarketresearch.com/scar-pipeline-review-h1-2015-market-report.html.
The report also reviews key players involved in the therapeutic development for Scar and special features on late-stage and discontinued projects. Companies discussed in this Scar – Pipeline Review, H1 2015 report include 3M Drug Delivery Systems, AlbireoPharma, Altacor Ltd., Amakem NV, Beech Tree Labs, Inc., Biomolecular Therapeutics GmbH, BiOrion Technologies B.V., Clanotech AB, Critical Outcome Technologies Inc., Derma Sciences, Inc., Easton Pharmaceuticals Inc., Escape Therapeutics, Inc., EyeGene, Inc., Fibrocell Science, Inc., FirstString Research, Inc., Juventas Therapeutics, Inc., Kasiak Research Pvt. Ltd., Pergamum AB, RXi Pharmaceuticals Corporation and Symic Biomedical, Inc.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Drug Profiles mentioned in this report are A-3914, A-5425, AMA-0526, azficel-T, BMT-101, BOT-191, BTL-slo, CLT-28643, CM-101, decorin, Drug to Agonize Beta 2 Receptor for Wound Scars, DSC-127, EGS-001, EP-003, FibroStem, Granexin, ICX-RHY, JVS-100, nefopam hydrochloride, PXL-01, Refaglo, RXI-109, S-34240, Small Molecules for Wounds and Scars, Small Molecules to Activate SOX-9 for Scar, Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology and tranilast. Order a purchase copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=356483. (This is a premium report priced at US$2000 for a single user License.)
Featured News & Press Releases cover by this report include: Dec 17, 2014: RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 96, Sep 29, 2014: RXi Pharmaceuticals to Present at the 13th Annual BIO Investor Forum 97, Mar 05, 2014: RXi Pharmaceuticals Granted Key Patent Related to Self-Delivering Technology for the Treatment of Fibrotic Disorders 97, Feb 03, 2014: RXi Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference 98, Dec 04, 2013: RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period 98, Nov 18, 2013: RXi Pharmaceuticals and Ethicor Announce the Signing of a Distribution Agreement for RXI-109 in the European Union under the "Specials" Provision 99, Jul 15, 2013: FirstString Research, Inc. Announces the Achievement of Primary Endpoints in Three Phase 2 Clinical Trials of Granexin Gel for the Treatment of Chronic Wounds and Scar Reduction 99, Jul 12, 2013: RXi Pharmaceuticals Announces Positive Data in Second Phase 1 Multi-Dose Study 100, Jun 27, 2013: Pergamum Reports Positive Follow-up Data From Phase II Clinical Trial Of PXL-01 For Prevention Of Post-surgical Adhesions 101 and Jun 06, 2013: RXi Pharmaceuticals Announces Positive Results In First Double Blind Study In Healthy Volunteers With RXI-109 101.
List of Tables
Number of Products under Development for Scar, H1 2015 10
Number of Products under Development for Scar - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Investigation by Universities/Institutes, H1 2015 14
Comparative Analysis by Late Stage Development, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Products under Development by Companies, H1 2015 18
Products under Development by Companies, H1 2015 (Contd..1) 19
Products under Investigation by Universities/Institutes, H1 2015 20
Assessment by Monotherapy Products, H1 2015 41
Number of Products by Stage and Target, H1 2015 43
Number of Products by Stage and Mechanism of Action, H1 2015 45
Number of Products by Stage and Route of Administration, H1 2015 47
Number of Products by Stage and Molecule Type, H1 2015 49
Scar Therapeutics - Recent Pipeline Updates, H1 2015 82
Scar - Dormant Projects, H1 2015 94
Scar - Discontinued Products, H1 2015 95
Explore more reports on Dermatology therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/dermatology-therapeutics.
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.